{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:11Z","timestamp":1794047351596,"version":"4.8.0"},"reference-count":60,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chitotriosidase activity and CCL18 concentration are interchangeably used for monitoring Gaucher disease (GD) activity, together with clinical assessment. However, comparative studies of these two biomarkers are scarce and of limited sample size. The aim of this systematic review with meta-analysis of individual participant data (IPD) was to compare the accuracy of chitotriosidase activity and CCL18 concentration for assessing type I GD severity. We identified cross-sectional and prospective cohort studies by searching Medline, EMBASE, and CENTRAL from 1995 to June 2017, and by contacting research groups. The primary outcome was a composite of liver volume &gt;1.25 multiple of normal (MN), spleen volume &gt;5 MN, hemoglobin concentration &lt;11 g\/dL, and platelet count &lt;100x109\/L. Overall, IPD included 1109 observations from 334 patients enrolled in nine primary studies, after excluding 111 patients with undocumented values and 18 patients with deficient chitotriosidase activity. IPD were unavailable for 14 eligible primary studies. The primary outcome was associated with a 5.3-fold (95% confidence interval [CI], 4.2 to 6.6) and 3.0-fold (95% CI, 2.6 to 3.6) increase of the geometric mean for chitotriosidase activity and CCL18 concentration, respectively. The corresponding areas under the receiver operating characteristics curves were 0.82 and 0.84 (summary difference, 0.02, 95% CI, -0.02 to 0.05). The addition of chitotriosidase activity did not improve the accuracy of CCL18 concentration. Estimates remained robust in the sensitivity analysis and consistent across subgroups. Neither chitotriosidase activity nor CCL18 concentration varied significantly according to a recent history of bone events among 97 patients. In conclusion, CCL18 concentration is as accurate as chitotriosidase activity in assessing hematological and visceral parameters of GD severity and can be measured in all GD patients. This meta-analysis supports the use of CCL18 rather than chitotriosidase activity for monitoring GD activity in routine practice.<\/jats:p>","DOI":"10.3324\/haematol.2019.236083","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T14:35:18Z","timestamp":1580394918000},"page":"437-445","source":"Crossref","is-referenced-by-count":25,"title":["Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data"],"prefix":"10.3324","volume":"106","author":[{"family":"Tatiana Raskovalova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Patrick B. Deegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Pramod K. Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Elena Pavlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ruby Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ari Zimran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Juliette Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"C\u00e9line Bourgne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Bruno Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jos\u00e9 Labar\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Marc G. Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"20080","unstructured":"Zimran A, Elstein D. Chapter 72: Gaucher disease and related lysosomal storage diseases. 2016;1121-1131."},{"key":"20081","doi-asserted-by":"crossref","unstructured":"Charrow J, Andersson HC, Kaplan P. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000; 160(18):2835-2843.","DOI":"10.1001\/archinte.160.18.2835"},{"key":"20082","doi-asserted-by":"crossref","unstructured":"Grabowski GA, Zimran A, Ida H. Gaucher disease types 1 and 3: phenotypic characterization of large populations from the ICGG Gaucher Registry. Am J Hematol. 2015; 90(Suppl 1):S12-18.","DOI":"10.1002\/ajh.24063"},{"key":"20083","doi-asserted-by":"crossref","unstructured":"Zimran A, Belmatoug N, Bembi B. Demographics and patient characteristics of 1209 patients with Gaucher disease: descriptive analysis from the Gaucher Outcome Survey (GOS). Am J Hematol. 2018; 93(2):205-212.","DOI":"10.1002\/ajh.24957"},{"key":"20084","doi-asserted-by":"crossref","unstructured":"Nalysnyk L, Rotella P, Simeone JC. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology. 2017; 22(2):65-73.","DOI":"10.1080\/10245332.2016.1240391"},{"key":"20085","doi-asserted-by":"crossref","unstructured":"Mistry PK, Belmatoug N, Vom Dahl S. Understanding the natural history of Gaucher disease. Am J Hematol. 2015; 90(Suppl 1):S6-S11.","DOI":"10.1002\/ajh.24055"},{"key":"20086","doi-asserted-by":"crossref","unstructured":"Weinreb NJ, Aggio MC, Andersson HC. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol. 2004; 41(4 Suppl 5):S15-22.","DOI":"10.1053\/j.seminhematol.2004.07.010"},{"key":"20087","doi-asserted-by":"crossref","unstructured":"Boot RG, Verhoek M, de Fost M. Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood. 2004; 103(1):33-39.","DOI":"10.1182\/blood-2003-05-1612"},{"key":"20088","doi-asserted-by":"crossref","unstructured":"Dekker N, van Dussen L, Hollak CE. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011; 118(16):e118-127.","DOI":"10.1182\/blood-2011-05-352971"},{"key":"20089","doi-asserted-by":"crossref","unstructured":"Hollak CE, van Weely S, van Oers MH. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 1994; 93(3):1288-1292.","DOI":"10.1172\/JCI117084"},{"key":"20090","doi-asserted-by":"crossref","unstructured":"Aerts JM, Kallemeijn WW, Wegdam W. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J Inherit Metab Dis. 2011; 34(3):605-619.","DOI":"10.1007\/s10545-011-9308-6"},{"key":"20091","doi-asserted-by":"crossref","unstructured":"Deegan PB, Moran MT, McFarlane I. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis. 2005; 35(2):259-267.","DOI":"10.1016\/j.bcmd.2005.05.005"},{"key":"20092","doi-asserted-by":"crossref","unstructured":"van Dussen L, Hendriks EJ, Groener JE. Value of plasma chitotriosidase to assess nonneuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy. J Inherit Metab Dis. 2014; 37(6):991-1001.","DOI":"10.1007\/s10545-014-9711-x"},{"key":"20093","doi-asserted-by":"crossref","unstructured":"Smid BE, Ferraz MJ, Verhoek M. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients. Orphanet J Rare Dis. 2016; 11:28.","DOI":"10.1186\/s13023-016-0413-3"},{"key":"20094","doi-asserted-by":"crossref","unstructured":"Schoonhoven A, Rudensky B, Elstein D. Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin Chim Acta. 2007; 381(2):136-139.","DOI":"10.1016\/j.cca.2007.02.042"},{"key":"20095","doi-asserted-by":"crossref","unstructured":"Boot RG, Renkema GH, Verhoek M. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem. 1998; 273(40):25680-25685.","DOI":"10.1074\/jbc.273.40.25680"},{"key":"20096","doi-asserted-by":"crossref","unstructured":"Deegan PB, Pavlova E, Tindall J. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore). 2011; 90(1):52-60.","DOI":"10.1097\/MD.0b013e3182057be4"},{"key":"20097","doi-asserted-by":"crossref","unstructured":"Riley RD, Lambert PC, Abo-Zaid G. Metaanalysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010; 340:c221.","DOI":"10.1136\/bmj.c221"},{"key":"20098","doi-asserted-by":"crossref","unstructured":"Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. Stat Med. 1995; 14(19):2057-2079.","DOI":"10.1002\/sim.4780141902"},{"key":"20099","doi-asserted-by":"crossref","unstructured":"Stewart LA, Clarke M, Rovers M. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015; 313(16):1657-1665.","DOI":"10.1001\/jama.2015.3656"},{"key":"20100","doi-asserted-by":"crossref","unstructured":"Raskovalova T, Deegan PB, Yang R. Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant data. Syst Rev. 2017; 6(1):87.","DOI":"10.1186\/s13643-017-0483-x"},{"key":"20101","doi-asserted-by":"crossref","unstructured":"Hollak CE, Belmatoug N, Cole JA. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years. Br J Haematol. 2012; 158(4):528-538.","DOI":"10.1111\/j.1365-2141.2012.09175.x"},{"key":"20102","unstructured":"WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. 2011."},{"key":"20103","doi-asserted-by":"crossref","unstructured":"Bland JM, Altman DG. Transformations, means, and confidence intervals. BMJ. 1996; 312(7038):1079.","DOI":"10.1136\/bmj.312.7038.1079"},{"key":"20104","doi-asserted-by":"crossref","unstructured":"Bland JM, Altman DG. The use of transformation when comparing two means. BMJ. 1996; 312(7039):1153.","DOI":"10.1136\/bmj.312.7039.1153"},{"key":"20105","doi-asserted-by":"crossref","unstructured":"Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med. 2017; 36(5):855-875.","DOI":"10.1002\/sim.7141"},{"key":"20106","doi-asserted-by":"crossref","unstructured":"Stewart GB, Altman DG, Askie LM. Statistical analysis of individual participant data meta-analyses: a comparison of methods and recommendations for practice. PLoS One. 2012; 7(10):e46042.","DOI":"10.1371\/journal.pone.0046042"},{"key":"20107","doi-asserted-by":"crossref","unstructured":"Ben Turkia H, Gonzalez DE, Barton NW. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol. 2013; 88(3):179-184.","DOI":"10.1002\/ajh.23382"},{"key":"20108","doi-asserted-by":"crossref","unstructured":"Elstein D, Mehta A, Hughes DA. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease. Am J Hematol. 2015; 90(7):592-597.","DOI":"10.1002\/ajh.24007"},{"key":"20109","doi-asserted-by":"crossref","unstructured":"Gonzalez DE, Turkia HB, Lukina EA. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, Phase 3 study. Am J Hematol. 2013; 88(3):166-171.","DOI":"10.1002\/ajh.23381"},{"key":"20110","doi-asserted-by":"crossref","unstructured":"Zimran A, Altarescu G, Philips M. Phase 1\/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood. 2010; 115(23):4651-4656.","DOI":"10.1182\/blood-2010-02-268649"},{"key":"20111","doi-asserted-by":"crossref","unstructured":"Berger J, Vigan M, Pereira B. Intra-monocyte pharmacokinetics of imiglucerase supports a possible personalized management of Gaucher disease type 1. Clin Pharmacokinet. 2019; 58(4):469-482.","DOI":"10.1007\/s40262-018-0708-8"},{"key":"20112","doi-asserted-by":"crossref","unstructured":"Murugesan V, Chuang WL, Liu J. Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol. 2016; 91(11):1082-1089.","DOI":"10.1002\/ajh.24491"},{"key":"20113","doi-asserted-by":"crossref","unstructured":"Zimran A, Brill-Almon E, Chertkoff R. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011; 118(22):5767-5773.","DOI":"10.1182\/blood-2011-07-366955"},{"key":"20114","doi-asserted-by":"crossref","unstructured":"Zimran A, Gonzalez-Rodriguez DE, Abrahamov A. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease. Blood Cells Mol Dis. 2015; 54(1):9-16.","DOI":"10.1016\/j.bcmd.2014.10.002"},{"key":"20115","doi-asserted-by":"crossref","unstructured":"Andrade-Campos MM, Garcia-Sobreviela MP, Medrano-Engay B. Assessing underlying chronic inflammation status in type 1 Gaucher disease patients (GD1): Involvement of lipocaline (LCN2) and other monocyte cytokines. Mol Genet Metab. 2017; 120:S22.","DOI":"10.1016\/j.ymgme.2016.11.025"},{"key":"20116","doi-asserted-by":"crossref","unstructured":"Boot RG, Verhoek M, Langeveld M. CCL18: a urinary marker of Gaucher cell burden in Gaucher patients. J Inherit Metab Dis. 2006; 29(4):564-571.","DOI":"10.1007\/s10545-006-0318-8"},{"key":"20117","doi-asserted-by":"crossref","unstructured":"Di Rocco M, Giona F, Carubbi F. A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica. 2008; 93(8):1211-1218.","DOI":"10.3324\/haematol.12379"},{"key":"20118","doi-asserted-by":"crossref","unstructured":"Giraldo P, Alfonso P, Atutxa K. Realworld clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. Haematologica. 2009; 94(12):1771-1775.","DOI":"10.3324\/haematol.2009.008078"},{"key":"20119","doi-asserted-by":"crossref","unstructured":"Giraldo P, Irun P, Alfonso P. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage. Blood Cells Mol Dis. 2011; 46(1):115-118.","DOI":"10.1016\/j.bcmd.2010.09.005"},{"key":"20120","doi-asserted-by":"crossref","unstructured":"Giraldo P, P\u00e9rez-L\u00f3pez J, N\u00fa\u00f1ez R. Patients with type 1 Gaucher disease in Spain: a cross-sectional evaluation of health status. Blood Cells Mol Dis. 2016; 56(1):23-30.","DOI":"10.1016\/j.bcmd.2015.10.001"},{"key":"20121","doi-asserted-by":"crossref","unstructured":"Groener JE, Poorthuis BJ, Kuiper S. Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention. Biochim Biophys Acta. 2008; 1781(1-2):72-78.","DOI":"10.1016\/j.bbalip.2007.11.004"},{"key":"20122","doi-asserted-by":"crossref","unstructured":"Limgala RP, Ioanou C, Plassmeyer M. Time of initiating enzyme replacement therapy affects immune abnormalities and disease severity in patients with Gaucher disease. PLoS One. 2016; 11(12):e0168135.","DOI":"10.1371\/journal.pone.0168135"},{"key":"20123","doi-asserted-by":"crossref","unstructured":"Lukina E, Watman N, Dragosky M. Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis. 2014; 53(4):274-276.","DOI":"10.1016\/j.bcmd.2014.04.002"},{"key":"20124","doi-asserted-by":"crossref","unstructured":"Mistry PK, Lukina E, Ben Turkia H. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA. 2015; 313(7):695-706.","DOI":"10.1001\/jama.2015.459"},{"key":"20125","doi-asserted-by":"crossref","unstructured":"Pastores GM, Petakov M, Giraldo P. A phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. Blood Cells Mol Dis. 2014; 53(4):253-260.","DOI":"10.1016\/j.bcmd.2014.05.004"},{"key":"20126","doi-asserted-by":"crossref","unstructured":"Drugan C, Drugan TC, Grigorescu-Sido P. Modelling long-term evolution of chitotriosidase in non-neuronopathic Gaucher disease. Scand J Clin Lab Invest. 2017; 77(4):275-282.","DOI":"10.1080\/00365513.2017.1303191"},{"key":"20127","doi-asserted-by":"crossref","unstructured":"Stirnemann J, Belmatoug N, Vincent C. Bone events and evolution of biologic markers in Gaucher disease before and during treatment. Arthritis Res Ther. 2010; 12(4):R156.","DOI":"10.1186\/ar3111"},{"key":"20128","doi-asserted-by":"crossref","unstructured":"Boven LA, van Meurs M, Boot RG. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol. 2004; 122(3):359-369.","DOI":"10.1309\/BG5VA8JRDQH1M7HN"},{"key":"20129","doi-asserted-by":"crossref","unstructured":"Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003; 3(1):23-35.","DOI":"10.1038\/nri978"},{"key":"20130","doi-asserted-by":"crossref","unstructured":"Mantovani A, Sica A, Sozzani S. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25(12):677-686.","DOI":"10.1016\/j.it.2004.09.015"},{"key":"20131","doi-asserted-by":"crossref","unstructured":"Rolfs A, Giese AK, Grittner U. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS One. 2013; 8(11):e79732.","DOI":"10.1371\/journal.pone.0079732"},{"key":"20132","doi-asserted-by":"crossref","unstructured":"Gelb MH. Newborn screening for lysosomal storage diseases: methodologies, screen positive rates, normalization of datasets, second- tier tests, and post-analysis tools. Int J Neonatal Screen. 2018; 4(3)","DOI":"10.3390\/ijns4030023"},{"key":"20133","doi-asserted-by":"crossref","unstructured":"Charrow J, Scott CR. Long-term treatment outcomes in Gaucher disease. Am J Hematol. 2015; 90(Suppl 1):S19-24.","DOI":"10.1002\/ajh.24056"},{"key":"20134","doi-asserted-by":"crossref","unstructured":"Hollak CE, Maas M, Aerts JM. Clinically relevant therapeutic endpoints in type I Gaucher disease. J Inherit Metab Dis. 24; 24(Suppl 2):S97-105.","DOI":"10.1023\/A:1012492429191"},{"key":"20135","doi-asserted-by":"crossref","unstructured":"Shemesh E, Deroma L, Bembi B. Enzyme replacement and substrate reduction therapy for Gaucher disease. Cochrane Database Syst Rev. 2015; 3:CD010324.","DOI":"10.1002\/14651858.CD010324.pub2"},{"key":"20136","doi-asserted-by":"crossref","unstructured":"Sims KB, Pastores GM, Weinreb NJ. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet. 2008; 73(5):430-440.","DOI":"10.1111\/j.1399-0004.2008.00978.x"},{"key":"20137","doi-asserted-by":"crossref","unstructured":"Weinreb NJ, Cappellini MD, Cox TM. A validated disease severity scoring system for adults with type 1 Gaucher disease. Genet Med. 2010; 12(1):44-51.","DOI":"10.1097\/GIM.0b013e3181c39194"},{"key":"20138","doi-asserted-by":"crossref","unstructured":"Johnston BC, Miller PA, Agarwal A. Limited responsiveness related to the minimal important difference of patient-reported outcomes in rare diseases. J Clin Epidemiol. 2016; 79(11):10-21.","DOI":"10.1016\/j.jclinepi.2016.06.010"},{"key":"20139","doi-asserted-by":"crossref","unstructured":"Leeflang MM, Deeks JJ, Gatsonis C. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008; 149(12):889-897.","DOI":"10.7326\/0003-4819-149-12-200812160-00008"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9633\/70520","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9633\/70521","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9633\/70520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:55:54Z","timestamp":1794045354000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2019.236083","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,30]]}}}